Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN.

Arch Neurol. 2001 Jun;58(6):961-7.

PMID:
11405811
2.

Intrarater and interrater reliability of the MS functional composite outcome measure.

Cohen JA, Fischer JS, Bolibrush DM, Jak AJ, Kniker JE, Mertz LA, Skaramagas TT, Cutter GR.

Neurology. 2000 Feb 22;54(4):802-6.

PMID:
10690966
3.

The multiple sclerosis functional composite: different practice effects in the three test components.

Solari A, Radice D, Manneschi L, Motti L, Montanari E.

J Neurol Sci. 2005 Jan 15;228(1):71-4. Epub 2004 Nov 6.

PMID:
15607213
4.

Clinical outcome measures for research in multiple sclerosis.

Balcer LJ.

J Neuroophthalmol. 2001 Dec;21(4):296-301. Review.

PMID:
11756863
5.

The reliability of the MSFC and its components.

Rosti-Otajärvi E, Hämäläinen P, Koivisto K, Hokkanen L.

Acta Neurol Scand. 2008 Jun;117(6):421-7. Epub 2007 Dec 12.

PMID:
18081910
6.

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ.

Neurology. 2005 Mar 22;64(6):992-5.

PMID:
15781814
8.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.

Neurology. 2001 May 22;56(10):1324-30.

PMID:
11376182
9.

[Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2006 Nov 20;59(11-12):442-7. Hungarian.

PMID:
17203882
10.

Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.

Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS.

Arch Neurol. 2000 Sep;57(9):1319-24.

PMID:
10987899
11.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators..

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157
12.

[Multiple Sclerosis Functional Composite Measure (MSFC) standardized in the Brazilian population].

Tilbery CP, Mendes MF, Thomaz RB, Oliveira BE, Kelian GL, Busch R, Miranda PP, Caleffi P.

Arq Neuropsiquiatr. 2005 Mar;63(1):127-32. Epub 2005 Apr 13. Portuguese.

13.

[Application of the Multiple Sclerosis Functional Composite in Debrecen].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2005 Mar 20;58(3-4):113-8. Hungarian.

PMID:
15887414
14.

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.

Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying GS, Galetta SL, Maguire MG, Cutter GR.

Neurology. 2003 Nov 25;61(10):1367-73.

PMID:
14638957
15.

The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Polman CH, Rudick RA.

Neurology. 2010 Apr 27;74 Suppl 3:S8-15. doi: 10.1212/WNL.0b013e3181dbb571. Review.

PMID:
20421572
16.
17.

MS functional composite: relation to disease phenotype and disability strata.

Kalkers NF, de Groot V, Lazeron RH, Killestein J, Adèr HJ, Barkhof F, Lankhorst GJ, Polman CH.

Neurology. 2000 Mar 28;54(6):1233-9.

PMID:
10746590
18.

Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.

Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G; Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients study group..

J Neurol. 2010 Apr;257(4):584-9. doi: 10.1007/s00415-009-5378-x. Epub 2009 Nov 18.

PMID:
19921303
19.

Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.

Kalkers NF, Bergers L, de Groot V, Lazeron RH, van Walderveen MA, Uitdehaag BM, Polman CH, Barkhof F.

Neurology. 2001 Jan 23;56(2):215-9.

PMID:
11160958
20.

A study validating changes in the multiple sclerosis functional composite.

Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH.

Arch Neurol. 2002 Jan;59(1):113-6.

PMID:
11790238

Supplemental Content

Support Center